Literature DB >> 27527810

Expression of several cytokines in prostate cancer: Correlation with clinical variables of patients. Relationship with biochemical progression of the malignance.

Norelia Torrealba1, Gonzalo Rodríguez-Berriguete2, Benito Fraile3, Gabriel Olmedilla4, Pilar Martínez-Onsurbe5, Manuel Guil-Cid6, Ricardo Paniagua7, Mar Royuela8.   

Abstract

BACKGROUND: This work is focused on finding new markers that complement or diagnoses currently used towards improving knowledge histological and statistical aspects that allow us to predict the local stage carcinomas and to identify and understand all the factors related to the progression of this disease.
MATERIALS AND METHODS: Prostates were obtained from: normal prostates from 20 men, diagnosis of BPH (Benign Prostatic Hyperplasia) from 35 men and prostate cancer from 86 men. We studied the behavior of cytokines that have been implicated in inflammatory processes: TNF-alfa, IL-6, IL-1, EGF and TGF-B. Expression of these cytokines and its receptors was analyzed by immunohistochemistry. Spearman's test, Kaplan-Meier curves, univariate and multivariate Cox proportional hazard regression analyses were performed.
RESULTS: Spearman's analysis showed that there was at least one correlation between TGFB-B, IL-6, gp-130, IL-1B, IL-1R, IL-1RII and clinic pathological feature (preoperative serum PSA, clinical t stage, pathological t stage, positive surgical margins, biochemical progression, survival). Immunostaining score was correlated with some of the clinicopathological feature. In Cox multivariate analysis between the prognostic variables (pathological T stage, Gleason score and lymph node) and immunohistochemical parameters (TGF-B, IL-1a, intensity TGFBRI and intensity TGFBRII) only the expression of IL-1a was retained as independent predictors of biochemical progression after radical prostatectomy.
CONCLUSIONS: Our results suggest a role for prostatic expression of TGF-B, IL-1a, TGFBRI and TGFBRII as prognostic markers for prostate cancer. The rational combination of novel agents directed toward the inactivation of TGF-B, IL-1a, TGFBRI and TGFBRII could disrupt complementary tumor cell proliferation pathways.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EGF; IL-1; IL-6; TGF-B and prostate cancer; TNF-alfa

Mesh:

Substances:

Year:  2016        PMID: 27527810     DOI: 10.1016/j.cyto.2016.08.008

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

1.  Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats.

Authors:  Bianca Facchim Gonçalves; Silvana Gisele Pegorin de Campos; Wagner José Fávaro; Joyce Zalotti Brandt; Cristiane Figueiredo Pinho; Luis Antônio Justulin; Sebastião Roberto Taboga; Wellerson Rodrigo Scarano
Journal:  Horm Cancer       Date:  2018-01-23       Impact factor: 3.869

2.  Nrf2 antioxidant pathway and apoptosis induction and inhibition of NF-κB-mediated inflammatory response in human prostate cancer PC3 cells by Brassica oleracea var. acephala: An in vitro study.

Authors:  Mehri Nazeri; Houshang Nemati; Mozafar Khazaei
Journal:  Mol Biol Rep       Date:  2022-05-26       Impact factor: 2.742

3.  Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.

Authors:  Jessica E Hawley; Samuel Pan; William D Figg; Zoila A Lopez-Bujanda; Jonathan D Strope; David H Aggen; Matthew C Dallos; Emerson A Lim; Mark N Stein; Jianhua Hu; Charles G Drake
Journal:  Prostate       Date:  2020-01-03       Impact factor: 4.104

Review 4.  The Role of NF-κB in Uterine Spiral Arteries Remodeling, Insight into the Cornerstone of Preeclampsia.

Authors:  Maciej W Socha; Bartosz Malinowski; Oskar Puk; Mateusz Wartęga; Martyna Stankiewicz; Anita Kazdepka-Ziemińska; Michał Wiciński
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 5.  Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.

Authors:  Hisham F Bahmad; Mohammad Jalloul; Joseph Azar; Maya M Moubarak; Tamara Abdul Samad; Deborah Mukherji; Mohamed Al-Sayegh; Wassim Abou-Kheir
Journal:  Front Genet       Date:  2021-03-26       Impact factor: 4.599

6.  Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2.

Authors:  Mohamed Raafat; Amr A Kamel; Alaa H Shehata; Al-Shaimaa F Ahmed; Asmaa M A Bayoumi; Rabab A Moussa; Mohammed A S Abourehab; Mahmoud El-Daly
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-22

Review 7.  Role of Interleukin-1 family in bone metastasis of prostate cancer.

Authors:  Yuanhao Tong; Yinghao Cao; Tianzhe Jin; Zhengwei Huang; Qinyuan He; Min Mao
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

8.  Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells.

Authors:  Xilin Xiong; Yang Li; Ling Liu; Kai Qi; Chi Zhang; Yueqin Chen; Jianpei Fang
Journal:  Biol Res       Date:  2018-06-13       Impact factor: 5.612

9.  Genome-wide association analysis reveals regulation of at-risk loci by DNA methylation in prostate cancer.

Authors:  Qiang Liu; Gang Liu; Darryl T Martin; Yu-Tong Xing; Robert M Weiss; Jun Qi; Jian Kang
Journal:  Asian J Androl       Date:  2021 Sep-Oct       Impact factor: 3.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.